Peptides for Weight Loss & Metabolic Health

FDA-approved (March 2021) glucagon receptor agonist analog for the treatment of severe hypoglycemia in pediatric (age 6+) and adult patients with...

Dulaglutide is a once-weekly subcutaneous GLP-1 receptor agonist marketed as Trulicity, FDA-approved for glycemic control in adults and pediatric...

FDA-approved GLP-1 receptor agonist for type 2 diabetes, derived from Gila monster venom peptide exendin-4, with consistent evidence for weight...

An FDA-approved long-acting somatostatin analog (brand: Somatuline Depot) indicated for acromegaly, gastroenteropancreatic neuroendocrine tumors...

Liraglutide is an FDA-approved once-daily GLP-1 receptor agonist used for type 2 diabetes (Victoza) and chronic weight management (Saxenda), with...

FDA-approved (2016) once-daily short-acting prandial GLP-1 receptor agonist for type 2 diabetes, marketed as Adlyxin (US, discontinued 2023) and...

Octreotide is an FDA-approved synthetic somatostatin analogue that suppresses growth hormone, IGF-1, and gastrointestinal hormones, used primarily...

Pramlintide (brand name Symlin) is a synthetic analog of human amylin, an FDA-approved injectable peptide used as adjunctive therapy to mealtime...

A long-acting GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Administered...

Setmelanotide (IMCIVREE) is an FDA-approved cyclic peptide MC4R agonist used specifically for chronic weight management in adults and pediatric...

Teduglutide is an FDA- and EMA-approved GLP-2 receptor agonist indicated for Short Bowel Syndrome (SBS) in adults and pediatric patients aged 1 year...

An FDA-approved synthetic GHRH analog with N-terminal lipid modification, indicated for reduction of excess visceral abdominal fat in HIV-infected...

A first-in-class dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound)....

Vasopressin (arginine vasopressin, AVP) is an endogenous cyclic nonapeptide hormone and FDA-approved vasopressor that acts via V1a (Ki ~4.70 nM), V1b...

Investigational once-weekly long-acting amylin receptor agonist developed by Novo Nordisk for obesity and type 2 diabetes. Phase 3 RCTs show...

Investigational once-weekly fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) by Novo Nordisk that achieved...

A novel cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences, approved by China's NMPA for adult type 2 diabetes (January 2026) and...

Retatrutide (LY3437943) is an investigational triple agonist for the GIP, GLP-1, and glucagon receptors developed by Eli Lilly. Phase 2 trials showed...

Survodutide is an investigational dual glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) agonist peptide developed by Zealand Pharma and licensed...

Synthetic hexapeptide ghrelin receptor (GHS-R1a) agonist that potently stimulates GH release, approved in Japan as a diagnostic agent for GH...

GHRP-6 is a synthetic hexapeptide ghrelin mimetic that stimulates pulsatile GH release via the GHS-R1a receptor, with multiple small human endocrine...

MK-677 (ibutamoren) is an orally active, non-peptide growth hormone secretagogue that mimics ghrelin at the GHS-R1a receptor, producing sustained...

A synthetic 29-amino acid analog of endogenous human GHRH that stimulates pituitary growth hormone release. Previously FDA-approved for pediatric GH...

Adipotide (FTPP) is a chimeric peptidomimetic that induces targeted apoptosis of white adipose tissue vasculature via cell-surface prohibitin,...

A long-acting synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates sustained growth hormone and IGF-1 secretion through a Drug...

A highly selective synthetic pentapeptide agonist of the ghrelin receptor (GHS-R1a) that stimulates robust, pulsatile growth hormone release from the...

A 24-amino acid mitochondrial-derived peptide (MDP) first discovered in 2001 from surviving neurons of Alzheimer's disease brain tissue, with...